Yujie Zhang

Mr. Yujie Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
YZYujie Zhang
Yujie Zhang
JCJingjie Cao
Jingjie Cao
JSJiahan Su
Jiahan Su
THTingting He
Tingting He
QWQianru Wang
Qianru Wang
JZJing Zeng
Jing Zeng
Bitespiramycin, has been shown to have a therapeutic effect against respiratory tract inflammation, including a potential effect against COVID-19. A current clinical trial in China showed that bitespiramycin was an effective treatment for severe pneumonia and intracranial infection. However, there is lack of an analytical method to elucidate the distribution of bitespiramycin. In this study, a highly sensitive, rapid and reliable UPLC–MS/MS method was developed to comprehensively characterize the bitespiramycin distribution in various bio-samples, which is significantly improved upon the published work. A rapid sample preparation method was developed by using n-butanol as the solvent to extract bitespiramycin from different bio-samples. The extract was then directly analyzed by UPLC–MS/MS coupled with an alkaline-resistant column after centrifugation which avoids the time-consuming concentration process under nitrogen and redissolution. The method was employed to accurately quantify bitespiramycin and its metabolites in rat plasma, tissues, and human cerebrospinal fluid. Notably, the presence of bitespiramycin and its metabolites was identified for the first time in various rat organs including brain, testis, bladder and prostate as well as in human cerebrospinal fluid. This newly developed approach shows great promise for drug distribution assays including other antibiotics and can help elucidate the ADME of bitespiramycin.

5 June 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
YZYujie Zhang
Yujie Zhang
QWQinghong Wang
Qinghong Wang
YWYanjun Wang
Yanjun Wang
YWYongfu Wu
Yongfu Wu
Xun TianXun Tian
Xun Tian
YCYugang Cai
Yugang Cai
Objectives: This study aimed to employ a High Performance Liquid Chromatography coupled with Quadrupole Time-of-Flight Mass Spectrometry(HPLC-QTOF/MS) system to detect potential metabolites of 2-Fluorodeschloroketamine (2-FDCK) and 2-fluoro-N-ethylketamine (2-FXE) in rats, elucidate their metabolic pathways, and analyze the metabolic differences between the two compounds. Such exploration is vital for understanding their distinct drug effects and providing a reference for forensic toxicological assessment of new phencyclidine-class psychoactive substances. Methods: Twelve SD rats were randomly split into two groups. After a 12 h fast, each group was administered a single intraperitoneal injection of one drug at 0.045 mg/kg. At 1 h and 2 h post-dosing, the rats were euthanized, and blood, liver tissue, and urine samples were promptly collected. These samples underwent rapid solvent extraction for pretreatment and were then analyzed using HPLC-QTOF. Metabolites were identified through database searches and secondary mass spectrometry fragment ion analysis. Results: Comparative analysis of metabolite types, formation times, and chromatographic peak response intensities between the two groups showed that metabolic pathways were mostly consistent. However, significant differences were observed in metabolic reaction types, metabolite formation times, and response intensities, likely stemming from chemical structural disparities. Conclusions: The findings offer crucial insights into the drug effect differences between the two compounds and establish a valuable reference for forensic toxicological evaluation of new phencyclidine-class psychoactive substances.